Highlight
– ENTF brain stimulation therapy applied in the subacute phase post-ischemic stroke significantly increases the rate of patients achieving freedom-from-disability (mRS 0-1) at 8 to 12 weeks.
– Pooled analysis of two randomized, double-blind, sham-controlled trials (BQ3 and EMAGINE 1) including 124 patients confirmed improved disability outcomes and a favorable safety profile.
– The therapy led to a significant ordinal shift in disability levels and showed promising but non-significant benefits on upper extremity motor function.
– ENTF neuromodulation presents a promising non-invasive neurorehabilitation approach for moderate to severe post-stroke disability, warranting further large-scale investigations.
Study Background
Ischemic stroke remains a leading cause of adult disability worldwide, with many survivors suffering prolonged motor and functional impairment that severely affects quality of life. Recovery after stroke involves complex neural plasticity and reorganization processes. Despite advances in acute stroke management, effective therapies to enhance functional recovery and reduce long-term disability during the subacute phase are limited.
Neuromodulation techniques have emerged as innovative interventions to influence brain networks and promote recovery. Electromagnetic Network-Targeted Field (ENTF) brain stimulation is a novel, non-invasive electromagnetic therapy aimed at modulating neural circuits implicated in post-stroke disability. Preliminary pilot studies suggested ENTF is safe and may foster recovery, meriting a pooled evaluation to define therapeutic efficacy more robustly.
Study Design
This meta-analysis combined individual participant data from two double-blind, randomized, sham-controlled trials: the BrainQ3 Trial (BQ3, NCT04039178) and the Electromagnetic Field Ischemic Stroke-Novel Subacute Treatment Trial (EMAGINE 1, NCT05044507). Both trials enrolled patients aged 4 to 21 days following an ischemic stroke with moderate to severe motor impairment, specifically an initial Fugl-Meyer Assessment–Upper Extremity (FMA-UE) score between 10 and 45. EMAGINE 1 additionally required a modified Rankin Scale (mRS) score of 3 to 4 at study entry.
Participants were randomized to receive either active ENTF neuromodulation or sham stimulation. The primary endpoint was the proportion of patients achieving freedom-from-disability, defined as mRS scores 0 to 1 at 8 to 12 weeks post-treatment. Secondary outcomes included changes in the level and ordinal distribution of disability assessed by mRS, as well as focused upper extremity motor function endpoints.
Key Findings
The pooled dataset included 124 patients (65 active ENTF, 59 sham), with balanced baseline characteristics: mean age 58.2 years, 31% female, average FMA-UE score of 25.3, and mean starting time of therapy 14.5 days poststroke.
At 8 to 12 weeks, freedom-from-disability was significantly higher in the ENTF group compared to sham (33.8% vs. 11.9%; P=0.005). This indicates that approximately one-third of treated patients regained functional independence, compared to about one-tenth in the control group. Moreover, an ordinal shift analysis demonstrated a significant improvement favoring ENTF across three disability strata (mRS scores 0-1, 2, >2; P=0.009), suggesting that ENTF therapy not only helps achieve independence but also reduces overall disability severity.
Upper extremity motor outcomes showed numerical, though statistically non-significant, trends favoring ENTF over sham, suggesting potential for motor recovery benefits that require larger samples for confirmation.
Importantly, safety evaluations revealed no device- or procedure-related serious adverse events, underscoring an excellent safety profile for ENTF neuromodulation.
Expert Commentary
This meta-analysis offers compelling evidence supporting ENTF brain stimulation as a feasible and efficacious modality for enhancing functional recovery after ischemic stroke in the subacute period. The statistically significant improvement in freedom-from-disability is clinically meaningful, indicating potential to shift standard rehabilitation paradigms.
Mechanistically, ENTF is theorized to modulate damaged neural networks by delivering targeted electromagnetic fields that facilitate neuroplasticity, reorganization, and functional restitution. This aligns with the growing understanding of stroke recovery as a network-driven process beyond isolated cortical areas.
While the results are promising, the modest sample size and short follow-up warrant cautious optimism. Upper extremity motor outcome improvements, although directionally positive, were not statistically significant, highlighting the need for larger randomized trials with longer follow-up intervals to fully characterize the scope of functional benefits and durability of effect.
Future studies should also explore the optimal timing, dosing, and patient selection criteria for ENTF therapy to maximize efficacy. Integration of ENTF with conventional rehabilitation strategies may provide synergistic benefits.
Conclusion
The pooled individual patient data meta-analysis from two rigorously conducted randomized controlled trials demonstrates that ENTF neuromodulation significantly reduces disability and improves recovery outcomes in patients with subacute moderate to severe ischemic stroke. Its favorable safety profile and clinically significant impact on disability underscore ENTF’s potential as a novel adjunct in stroke rehabilitation.
This evidence supports further confirmatory phase III trials and development toward routine clinical application, potentially transforming post-stroke recovery to improve patient independence and quality of life.
Funding and Clinical Trial Registration
The original studies, BrainQ3 Trial (NCT04039178) and EMAGINE 1 Trial (NCT05044507), were funded by institutional and grant support as detailed in their respective protocols. No serious conflicts of interest were reported in relation to the pooled analysis.
References
- Saver JL, Stein J, Cramer SC, Duncan PW, Weisinger BS, Pandey DP, Bornstein NM. ENTF Neuromodulation Yields Reduced Disability After Stroke: An Individual Participant-Level Data Meta-Analysis. Stroke. 2026 Jul 1; PMID: 42381628.
- Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S. The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance. Scand J Rehabil Med. 1975;7(1):13-31.
- van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver Agreement for the Assessment of Handicap in Stroke Patients. Stroke. 1988;19(5):604-607.
- Hara K. Brain plasticity and rehabilitation in stroke patients. J Nippon Med Sch. 2007 Jun;74(2):18-24.